TY - JOUR
T1 - Near infrared photoimmunotherapy for cancers
T2 - A translational perspective
AU - Maruoka, Yasuhiro
AU - Wakiyama, Hiroaki
AU - Choyke, Peter L.
AU - Kobayashi, Hisataka
N1 - Funding Information:
This research was supported by the Intramural Research Program of the National Institutes of Health, ZIA BC011513.
Funding Information:
This research was supported by the Intramural Research Program of the National Institutes of Health , National Cancer Institute , Center for Cancer Research (ZIA BC011513 ). The funders have no roles in experimental design, data collection and analysis, interpretation of the data, or writing of this paper.
Publisher Copyright:
© 2021
PY - 2021/8
Y1 - 2021/8
N2 - Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye, IRDye700DX (IR700). The antibody conjugate is injected into the patient and accumulates in the tumour. Within 24 h of injection the tumour is exposed to NIR light which activates the conjugate and causes rapid, selective cancer cell death. A global phase III clinical trial of NIR-PIT in recurrent head and neck squamous cell cancer (HNSCC) patients is currently underway. Conditional clinical approval for NIR-PIT in recurrent HNSCC has been granted in Japan as of September 2020. Not only does NIR-PIT induce highly selective and immediate cancer cell killing, but it also stimulates highly active anti-tumour immunity. While monotherapy with NIR-PIT has proven effective it is likely that combinations with immune-checkpoint inhibitors or additional NIR-PIT targeting immune suppressive cells in the tumour microenvironment will further improve results. In this review, we discuss the translational aspects of NIR-PIT especially in HNSCC, and potential future applications.
AB - Near-infrared photoimmunotherapy (NIR-PIT) is a newly-developed, highly-selective cancer treatment, which utilizes a monoclonal antibody conjugated to a photoabsorbing dye, IRDye700DX (IR700). The antibody conjugate is injected into the patient and accumulates in the tumour. Within 24 h of injection the tumour is exposed to NIR light which activates the conjugate and causes rapid, selective cancer cell death. A global phase III clinical trial of NIR-PIT in recurrent head and neck squamous cell cancer (HNSCC) patients is currently underway. Conditional clinical approval for NIR-PIT in recurrent HNSCC has been granted in Japan as of September 2020. Not only does NIR-PIT induce highly selective and immediate cancer cell killing, but it also stimulates highly active anti-tumour immunity. While monotherapy with NIR-PIT has proven effective it is likely that combinations with immune-checkpoint inhibitors or additional NIR-PIT targeting immune suppressive cells in the tumour microenvironment will further improve results. In this review, we discuss the translational aspects of NIR-PIT especially in HNSCC, and potential future applications.
UR - http://www.scopus.com/inward/record.url?scp=85111264058&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111264058&partnerID=8YFLogxK
U2 - 10.1016/j.ebiom.2021.103501
DO - 10.1016/j.ebiom.2021.103501
M3 - Review article
C2 - 34332294
AN - SCOPUS:85111264058
VL - 70
JO - EBioMedicine
JF - EBioMedicine
SN - 2352-3964
M1 - 103501
ER -
